Danish pharma major Novo Nordisk has announced the launch of Ozempic (injectable semaglutide) in India. The popular once-a-week injection to help manage Type 2 diabetes will be available at a starting dose of 0.25 mg priced at Rs 2,200 per week.

The announcement was made on Friday by Vikrant Shrotriya, MD, Novo Nordisk. On the occasion, Dr A G Unnikrishnan, Chief of Endocrinology at The Chellaram Diabetes Institute, Pune and Dr Shashank Joshi, consultant endocrinologist at Lilavati Hospital, Mumbai joined in to caution that it was also vital to ensure that the drug is given to the correct patient under medical supervision.

What is Ozempic?

Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living with uncontrolled type 2 diab

See Full Page